Cancer cells that detach from solid tumor and circulate in the peripheral blood (CTCs) have been considered as a new "biomarker" for the detection and characterization of cancers.
Introduction
Tumor metastasis, the process by which cancer cells leave primary tumor and colonize distant sites, is the common cause of mortality for cancer patients with solid malignant tumors (1) . Being observed since 1869, circulating tumor cells (CTCs) (2) , which are defined as cancer cells detaching from the solid tumor and circulating within peripheral blood (3) , have been considered to play a crucial role in tumor metastasis and disease progression. In the past decade, abundant evidence has been provided to support the idea that CTC counts could serve as prognostic indicators for predicting clinic outcomes and monitoring treatment responses (4) (5) (6) (7) . For example, metastatic breast cancer patients with 5 or more CTCs counts (enumerated by CellSearch-Veridex) in 7.5 mL whole blood before Technology in Cancer Research & Treatment 2014 June 30. Epub ahead of print treatments are reported to suffer poorer progression-free survival and overall survival (8) . More importantly, CTCs, regarded as "liquid biopsy", provide an alternative access to solid tumor, which enables serial sampling for the study of tumor genomic variations (9) throughout the whole treatment and gives guidance to new drug discovery and personalized therapy. However, in absence of effective enrichment, the analysis of CTCs is extremely challenging as they are such a small sub-population (a few to hundreds per mL) among a large number of hematologic cells (10 9 cells mL -1 ) (8, 10) in the peripheral blood. Thus, to fully explore the clinic value of CTCs, a robust platform with sufficient sensitivity, excellent biocompatibility but low cost is required for rare CTCs detections.
Previously, we have demonstrated a highly efficient CTCs capture assay using a transparent nanostructured substrates made of TiO 2 nanoparticles (11) . Enhanced local topographic interactions (12, 13) between cancer cells surface (e.g., microvilli) and the antibody coated nanoparticles lead to improved CTC capture efficiency. However, further applications of this platform were constrained by the contamination of the non-specifically captured white blood cells (WBCs), which is incompatible with many subsequent studies such as gene expression, gene mutation, polymorphism and genetic sequence test. It's urgent to develop a new assay to get high purity cancer cells for molecular and functional analysis.
Herein, on the basis of our previously reported nanostructured TiO 2 nanoparticles substrate, we develop a new CTC detection strategy by combining negative depletion and positive enrichment, which is capable of efficiently capturing high purity and viable cancer cells in patient blood samples. A biocompatible and surface roughness controllable TiO 2 nanofilm was deposited onto a glass slide to achieve enhanced topographic interactions with nanoscale cellular surface components (14, 15 ) (e.g., filopodia), again, anti-CD45 (16) (a leukocyte common antigen) and anti-EpCAM (17) (epithelial cell adhesion molecule) were then coated onto the surface of nanosubstrate for advance depletion of WBCs and specific isolation of CTCs, respectively. This method also exhibited high capture efficiency comparing to the traditional positive enrichment technologies based on single capture agent labeled nanosubstrate, such as our previously reported horizontally packed TiO 2 nanofibers (18) and TiO 2 nanoparticles substrate (11) . More importantly, the maximum number of background cells (WBCs) was removed and viable and functional cancer cells were isolated with high purity, which made these cancer cells available for subsequent studies. Finally, rare CTCs captured from colon cancer patient's peripheral blood sample using our nanostructured chip were identified by three-color immunocytochemistry. We conclude that this improved method is capable of isolating pure CTCs for subsequent molecular analysis.
Methods

Preparation of TiO 2 Nanoparticles Chip (19-21)
The TiO 2 nanoparticles chip was fabricated in polydimethylsiloxane (PDMS) using a standard soft lithography and replica molding method. The process has been reported previously (11) . The width and height of micro-channel were 1 mm and 1 mm, respectively. The PDMS with microchannel was reversible bonding with glass substrate. 1.0 g synthesized TiO 2 spheres (TiSP) (Sigma-Aldrich, St Louis, MO, USA) was dispersed into a mixture of 0.05 g lauric acid, 0.2 g ethyl cellulose and 10.0 mL terpinol and ethanol mixture solution (v/v 1:1) to form slurry. The TiSP slurry can be diluted with ethanol to a concentration of 5 mg mL -1 . Then the capillary force can drive the TiO 2 nanoparticles slurry filled the micro-channel. After baking at 708C for half hour, the PDMS was carefully peeled off from the glass substrate. The substrate with TiO 2 nanoparticles on the surface substrate was annealed at 5008C for 15 min. Finally the PDMS was aligned onto the patterned TiO 2 nanoparticles substrate.
Surface Modification with Antibody (22)
According to the previously established method (23), the TiO 2 nanoparticles chip was modified with 4% (v/v) 3-mercaptopropyl trimethoxysilane (MPTMS) (Sigma-Aldrich) in ethanol at room temperature for 1 h, then, the substrate was treated with the coupling agent N-y-maleimidobutyryloxy succinimide ester (GMBS, 0.25 mM) (Sigma-Aldrich) for 1 h make for GBMS attachment to the substrate, next, the substrate was treated with 20 μg mL -1 of streptavidin (SA) (Invitrogen, Carlsbad, CA, USA) at room temperature overnight, resulting in immobilization onto GMBS, and washed with 1X PBS to remove excess streptavidin before adding 10 μL biotinylated anti-human CD45 (Mouse IgG1, 2.5 μg mL -1 in PBS) (R&D Systems, Minneapolis, MN, USA) onto Negative depletion portion and 10 μL biotinylated anti-EpCAM (10 μg mL -1 in PBS) (R&D Systems) onto Positive enrichment portion, respectively.
Cells and Blood Samples
Colorectal cancer cell line (HCT116), gastric carcinoma cell line (MGC803) and cervical cancer cell line (HeLa) were harvested from Hubei Key Laboratory of Tumor Biological Behaviors. Cells were cultured in Dulbecco's modified eagle medium (DMEM, BD Biosciences, San Jose, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin solution at 378C under a humidified 5% CO 2 atmosphere. Whole blood samples from healthy donors were obtained from Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University (Wuhan, Hubei, P. R. China) according to a protocol by the Institutional Review Board (IRB) and cancer patients' blood samples were obtained from Department of Oncology, Zhongnan Hospital of Wuhan University (Wuhan, Hubei, P. R. China) under a separate IRB-approved protocol. All blood specimens were collected into anticoagulant tubes (EDTA K 2 , 2 mL, violet cap) (Wuhan Zhiyuan Medical Technology Co., Ltd., Wuhan, Hubei, China).
Cell Capture and Identification 1 mL cell suspension or patient peripheral blood samples were introduced onto TiO 2 nanoparticles chips at a flow rate of 8 μL min -1 . Then, the chip was rinsed with PBS for 10 min. The captured cells on the chip were fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich) in PBS for 10 min. Then, the chip was loaded with 0.2% Triton X-100 (Sigma-Aldrich) in PBS and incubated for 10 min in order to improve the permeability of the cell and to allow for intracellular staining, 25 μL blocking solution was then loaded (2% donkey serum in PBS/0.2% triton X-100) onto the chip and kept for 30 min at room temperature, followed by staining with anti-cytokeratin-PE (CAM5.2, conjugated with phycoerythrin) (BD Biosciences) and anti-human CD45-FITC (Ms IgG1, clone H130) (BD Biosciences, San Jose, CA, USA) overnight. 49, 6-diamidino-2-phenylindole dihydrochloride (DAPI, 0.33 μg mL -1 in DI water) was used for staining nuclear for 10 min. Finally, detecting and counting of targeted cells using the fluorescence microscope (IX81, Olympus, Tokyo, Japan). Captured CTCs on chip were photographed by using IPP software (Media Cybernetics Inc., Silver Spring, MD, USA).
Cell Capture from the Artificial CTC Blood Samples and Patient Blood Samples
The cell capture efficiency of the optimal capture conditions was validated with artificial CTC samples containing HCT116 cells: 1) 1 mL DMEM media containing HCT116 cells and 2) 1 mL human blood (healthy donor) containing HCT116 cells. After rinsing, followed by staining of anti-CK, anti-CD45 and DAPI, the specifically captured HCT116 cells were identified and counted on the substrates. 1.0 mL patient peripheral blood sample was introduced onto our chip according to the procedure described above.
Results and Discussion
The TiO 2 nanoparticles chip was composed of two functional components ( Figure 1A and 1B) : 1) the biotinylated anti-CD45 bioconjugated on TiO 2 nanofilm depleted WBCs and 2) horizontally packed TiO 2 nanofilm improved CTC-capture through combining cell-capture-agent (anti-EpCAM) and cancer cell-preferred nanoscale topography ( Figure 1C) . The captured cancer cells on the nanofilm substrate appeared as many extended pseudopodia ( Figure 1D ). This finding provided further evidence supporting the working mechanism of our nanostructure-based cell-capture approach. These two components were fabricated according to the previously established procedures (details in Methods). The roughness of the nanofilm substrates were controlled by changing the temperature and reaction time.
As illustrated in Figure 2A , the biotin-TiO 2 nanoparticles chips were prepared for cell capture. To assess how the surface roughness of TiO 2 nanoparticles chip impacts the capture yields, we prepared an EpCAM-positive cancer cell line (HCT116) in Dulbecco's modified Eagle medium (DMEM) at a concentration of 10 5 mL -1 and captured the spiked cells with anti-EpCAM-grafted substrates prepared with different surface roughness (ranging from 20 to 100 nm). As shown in Figure 2B , when the surface roughness of the substrates were around 85 nm, maximum cell capture yields were achieved for HCT116 cell line (approximately 76%). Therefore this optimal substrate was selected for subsequent studies. The effect of roughness on the cell capture yields can be attributed to the local topographic interactions between nanosubstrate and cancer cells.
The capture performance of TiO 2 nanoparticles chip was assessed with a 1.0 mL suspension of HCT116 cells (1000 cells mL -1 in DMED medium) at flow rate of 8, 16, 24, 32, 40 and 48 μL min -1 . As observed in Figure 2C , the highest cellcapture efficiency (76 6 2%) was accomplished at flow rate of 8 μL min -1 , the recovery efficiency of cell capture decreased significantly with increasing flow rate (up to 24 μL min -1 ), we ascertain 8 μL min -1 to be the maximal flow rate for subsequent studies to decrease shearing force in order to preserve potentially fragile CTCs. We then validated the cell capture efficiency of the anti-CD45 and anti-EpCAM coated TiO 2 nanoparticles chip by using a series of artificial blood samples prepared by spiking HCT116 cells into DMEM and healthy donor's blood at concentrations of approximately 50, 100, 250, 500, 1000 cells mL -1 . The results in Figure 2D indicated that the recovered cell numbers ranging from a few to hundreds CTCs mL -1 . Spiked HCT116 cells were captured from DMEM and healthy donor's blood with a yield of 76.1% and 63.6%, respectively. Finally, to illustrate the cell capture specificity and optimized cell capture performance of TiO 2 nanoparticles chip, we used two EpCAM-positive cancer cell lines-HCT116 (colorectal cancer cell line) and MGC803 (gastric carcinoma cell line) for specific cell capture, a non-specific cells line-HeLa (cervical cancer cell line) as an adherent epithelial cell control, and CD45-positive cell-WBCs as suspension lymphocyte control were used for a specific cell capture contrast experiment. For the EpCAMpositive cell and CD45-positive cell, the maximal cell capture yields were achieved, whereas only relatively low yields of non-specific cells were captured. Summarized results in Figure 2E supported the idea that the CD45 and EpCAMcoated substrates were capable of depleting WBCs, capturing HCT116, MGC803 cells, but not HeLa cells (optimal capture condition of TiO 2 nanofilm substrate with 8 μL min -1 ).
During the capability test of purity cancer cells capture using TiO 2 nanoparticle chips, we performed cell capture efficiency and purity studies using artificial blood samples which were prepared by spiking healthy donor's blood (containing ca. 4-10 3 10 6 WBCs mL -1 ) with HCT116 cells at a concentration of approximately 1000 cells mL -1 . 1 mL artificial blood samples were introduced onto TiO 2 nanoparticles chips at a flow rate of 8 μL min -1 . In parallel, positive enrichment without negative depletion method was also examined as a control. After rinsing, fixation, permeabilization, blocking, followed by staining with anti-CK, anti-CD45 and DAPI, the specifically captured HCT116 cells and non-specifically immobilized WBCs were identified on the Chips. The fluorescence stain results in Figure 3A showed that the Positive enrichment without Negative depletion method captured many more WBCs than Negative depletion with Positive enrichment method. Cell capture assay results in Figure 3B and 3C showed that Negative depletion with Positive enrichment method exhibited equally high capture yields but higher purity comparing to Positive enrichment without Negative depletion. 626 6 49 HCT116 and 2000-5000 WBCs were identified on the Negative depletion with Positive enrichment platform, and 644 6 32 HCT116 and 5000-10000 WBCs were identified on the Positive enrichment without Negative depletion platform. Our results in Figure 3 showed that there was significant difference in levels of preference between these two methods, which suggested that higher purity cancer cells in cancer patients' peripheral blood could potentially be captured by our platform for subsequent studies. Further, Cell viability was tested by FDA-PI assay at two stages: before capture and after capture. The results indicated that the cell viability reaches 84% (after capture), making these cells suitable for subsequent studies (Figure 3D-3F ). Because the captured cancer cells are alive, they could be captured from cancer patients and potentially be physically isolated for proteomic and genomic analyses.
In order to validate the clinical utility of our platform for rare cancer cells capture from cancer patient peripheral blood samples, we applied the optimized cell capture conditions to study colon cancer patient peripheral blood samples (preserved in EDTA-K2 tubes). 1.0 mL peripheral blood sample was introduced onto our chip, after negative depletion and positive enrichment, captured cells then rinsed with PBS, fixed with 4% PFA and then permeabilized with 0.02% Triton-X100. After that, captured cells were stained by PE-labeled anti-CK, FITC-labeled anti-CD45 and DAPI (14, 24) . Specifically captured CTCs (CK1/CD45-/DAPI1, 10 μm  cell sizes  30 μm) were identified from WBCs (CK-/CD451/DAPI1, sizes  15 μm) using fluorescence microscopy (Figure 4 ).
In general, these data demonstrated that our platform for follow-up studies (molecular analysis of purity CTCs captured from patients) was possible, but at the same time, there was not enough CTCs number in further analysis from this colon cancer patient.
Conclusion
In conclusion, CTCs isolation based on negative depletion and positive enrichment allowed the detection of cancer cells with high purity, exhibited similar capture yield comparing to traditional method. Regarding the strong desire of obtaining pure CTCs from patients for study in genetic analysis, we expect the improved method can be used for the potential clinical research in future (treatment responses monitor and patient prognosis indication).
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